The Problem (dine at your own risk) Of the 150 customers who ate dinner last night at the Palazzo di Sporcizie 66 had a fish entree, 72 a meat entree,

Slides:



Advertisements
Similar presentations
Cognition enhancing or neuroprotective compounds for the treatment of cognitive disorders: why? when? which? Lockhart BP, Lestage PJ. January 2003.
Advertisements

Simple Past, Past continuous and Past perfect tense
Indianapolis Discovery Network for Dementia Comparative Effectiveness Research Trial of Alzheimers Disease Drug: COMET-AD.
Alzheimer Disease Ibrahim Sales, Pharm.D. Assistant Professor of Clinical Pharmacy King Saud University
The Top Ten Reasons To Eat Breakfast 1. A better attention span, focus and better productivity 2.Maintaining a healthy weight 3.Setting an example for.
UNITED SPINAL ASSOCIATION AUGUST, 2014 Biologics & Biosimilars: An Overview 1.
Clinical Trials Medical Interventions
Probability Using Permutations and Combinations
Bell Work Three-course dinners can be made from the menu shown. Find the sample space for a dinner consisting of an appetizer, entrée, and dessert. Hint:
Testing People Scientifically.  Clinical trials are research studies in which people help doctors and researchers find ways to improve health care. Each.
Alzheimer’s Disease Angela Singh, PharmD Associate Professor of Pharmacy Practice Florida A&M University College of Pharmacy & Pharmaceutical Sciences.
ALZHEIMER’S PART 2. AD VIDEO
Fatima Chaudhry. Why this drug was developed According to the Centers for Disease Control and Prevention (CDC), an estimated 45 million adults in the.
Pharmacological Management. Only symptomatic treatment, there is no cure. Acetylcholinesterase inhibitors - Only for mild to moderate dementia –Donepezil.
Background and Objective In the recently reported Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial, the combination of ezetimibe/simvastatin (E/S)
Drugs A drug is any substance you put into your body that changes around your body’s chemistry.
News You Can Use… Pete Koval, PharmD Tiffany Wong, PharmD Candidate Cone Health Family Medicine June 2014.
Alzheimer’s Disease By: Chelcy Branon. Facts  In 2006, there were 26.6 million sufferers worldwide  Costs 100 billion dollars per year.
Medical University of Sofia, Faculty of Medicine Department of Pharmacology and Toxicology Alzheimer’s Disease Avi Gandhi (2009)
Cardiovascular Risk and NSAIDs Arthritis Advisory Committee Meeting November 29, 2006 Sharon Hertz, M.D. Deputy Director Division of Analgesia, Anesthesia,
Compound from Red Wine is Helpful to Slow the Development of Alzheimer Alzheimer is one of the most common diseases among the elderly as aging playing.
Improvement in behavioural symptoms in patients with moderate to severe Alzheimer’s disease (AD) by memantine: a pooled data analysis Gauthier S., Loft.
Atherosclerotic Disease of the Carotid Artery Atherosclerosis is a degenerative disease of the arteries resulting in plaques consisting of necrotic cells,
Consent for Research Study A study for patients newly diagnosed with advanced glioblastoma (brain cancer): Learning whether a PET scan with F-fluoromisonidazole.
FDA Health Psychology. FDA = Food & Drug Administration Part of Dept of Health & __________ Services.
Meadowland College Freshman Orientation August 24, 2010.
Take it Away! Subtracting is to take away- Making shorter, less, or smaller, The opposite of adding- Making longer, more, or taller.
Nonparametric Methods: Goodness-of-Fit Tests Chapter 15 Copyright © 2013 by The McGraw-Hill Companies, Inc. All rights reserved. McGraw-Hill/Irwin.
Meadowland College Freshman Orientation August 24, 2010.
Mystery Labyrinth Much / many He ate ___ bananas for breakfast. He drank ___ tea for dinner. He drank ___ glasses of milk. He ate ___ soup for.
Understanding Clinical Trials – Part 2 Georgianne Arnold, MD Professor of Pediatrics University of Pittsburgh Medical Center Pittsburgh Children’s Hospital.
Welcome and introduction William Tarnow-Mordi When printing handouts, please select ‘Notes Pages’ option in “Print what” menu in lower left area of Print.
Alzheimer’s Disease: Advances and Hope Trey Sunderland, M.D. Chief, Geriatric Psychiatry Branch National Institute of Mental Health Bethesda, Maryland.
1 PRIORITY MEDICINES FOR EUROPE AND THE WORLD Barriers to Pharmaceutical Innovation Richard Laing EDM/PAR WHO.
Purpose of Clinical Trials Assess safety and efficacy of Experimental treatments New combinations of drugs New approaches to surgery or radiation therapies.
Memantine (Ebixor) Joanne Lily Wombwell Senior Memory Clinic Nurse Hartington Unit, CNDRH.
ALZHEIMER’S DISEASE DIAGNOSIS and TREATMENT J. Wesson Ashford, M.D., Ph.D. Stanford / VA Alzheimer’s Center VAMC, Palo Alto, California October, 2004 Slides.
Manufacturer: Relypsa Inc. FDA Approval Date: October 21, 2015
Simple Past, Past continuous and Past perfect
Date of download: 6/24/2016 From: Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes: A Systematic Review and Meta-analysis Ann Intern Med.
Alzheimer's Disease. More than a century after its discovery, Alzheimer's disease is still destroying people's brains. The cause remains unknown. September.
What we like eating and drinking.
Copyright © 2005 American Medical Association. All rights reserved.
Proportion of patients that met the SRI-5 response criteria (A and C) and reasons for non-response (B and D) in trial 1 (A and B) and trial 2 (C and D).
Clinical Trials Medical Interventions
How to read a nutrition label
NASs approval time by therapeutic area:
Alzheimer’s Disease Medical University of Sofia, Faculty of Medicine
Foodborne Illnesses People become sick because food is not handled, prepared, cooked or stored correctly Challenges of Food Safety Time Language Literacy.
دانشیار دانشکده دندانپزشکی دانشگاه علوم پزشکی شهید صدوقی یزد
Clinical Trials.
Median approval time for new active substances approved by ICH agencies by approval year Methodology For each new active substance (NAS) approved between.
Percentage Key Message
11/30/2018 Using Delayed Start Design and Analysis to Investigate Potential Disease Modifying Effects in Alzheimer’s Disease.
Median submission gap, median approval time and percentage approved as expedited for new active substances (NASs) approved by six authorities:
Comparison of median approval time of NASs by year of submission vs
EMA: The European Medicines Agency
INTERNATIONALISATION – FOCUS ON EMA AND FDA
Originally presented by Drs. Daniel Levy, Richard H. Grimm, Steven E
PRISMA study flow diagram
I Can’t Find My Keys – Should I Be Worried?
Baseline Characteristics of the Subjects
Comparison of median approval time of NASs by year of submission vs
Эмийн гаж нөлөөг бүртгэн мэдээлэх, ач холбогдол
How to read a nutrition label
Treatment algorithm. Treatment algorithm. IPAH: idiopathic pulmonary arterial hypertension; APAH: associated pulmonary arterial hypertension; WHO-FC: World.
Classification Criteria for axSpA
 Conceptual diagram of acetylcholine system and disease and drug effects.  Conceptual diagram of acetylcholine system and disease and drug effects. Relative.
Prescribers’ responses rating their level of comfort on a scale of 1–5
You Don't Know JAK in IBD.
Presentation transcript:

The Problem (dine at your own risk) Of the 150 customers who ate dinner last night at the Palazzo di Sporcizie 66 had a fish entree, 72 a meat entree, the rest ate a vegan meal. Historically four in ten Palazzo’s customers who have a fish entree develop some stomach trouble within twelve hours of their meal. For meat eaters the rate is 3 in ten, while only one in ten vegans develops stomach trouble in that time limit. This morning at lunch you hear a person saying: “Yesterday I ate dinner at the Palazzo di Sporcizie, it was excellent, I had no trouble at all, except for the price.” Is the person you overheard most likely to be a fish eater, a meat eater, or a vegan?

The Problem (Let’s be serious now) 150 Alzheimer’s disease (AD) patients recently participated in a research study. Four medications are currently approved by regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to treat the cognitive manifestations of AD: three are acetylcholinesterase inhibitors and the other is memantine, an NMDA receptor antagonist.Food and Drug AdministrationEuropean Medicines Agency acetylcholinesterase inhibitors memantineNMDA receptor antagonist No drug has an indication for delaying or halting the progression of the disease.

The Problem (Continued) 44% of the AD patients participating in the study received an acetylcholinesterase inhibitor, 48% were treated with memantine, the remaining patients, due to their remarkably good physical conditions, received a placebo. memantine, Past research suggests that 40% of AD patients on an acetylcholinesterase inhibitor show remarkable improvement, the drug memantine improves the conditions of about 30% of the patients treated with it, and 10% of AD patients in good physical conditions show improvement if left untreated.memantine A patient picked at random from the 150 has shown no improvement. Which drug (or the placebo) is most likely to have been used with this patient?

The Solution(s) The sample space S has 150 sample points (customers/AD patients)

The Event of Interest is: For Dining Customers : No stomach trouble For AD patients : No improvement We do the calculations on the blackboard

We need to compute: (They must be “givens.”)